Alan David Dauer, M.D., F.A.C.P.
Education and Experience
| 1953-1956 | Bachelor of Science, Zoology, University of Michigan |
| 1962 | Doctor of Medicine, New York Medical College |
| 1962-1963 | Internship, Cedars of Lebanon Hospital (Cedars-Sinai Medical Center) |
| 1963-1965 | Residency, Cedars of Lebanon Hospital (Cedar-Sinai Medical Center) |
| 1965-1966 | Fellowship in Renal and Respiratory Physiology, Cedars-Sinai Medical Center |
| 1965-1966 | Post Doctoral Scholar of NIH Grant, University of California Los Angeles Medical School. |
| 1965-1966 | Associate Attending Internal Medicine Supervisor, Nephrology Clinic Cedars- Sinai Medical Center. |
| 1966-1998 | Private Practice in Whittier, California-Acquired by Friendly Hills Medical Group in 1991. |
| 1968-1998 | Director, Clinical Laboratory Colima Internal Medical Group. |
| 1975-1982 | Associate Clinical Professor of Medicine, University of Southern California School of Medicine. |
| 1976-1983 | Chief of Medical Staff, Whittier Hospital Medical Center |
| 1976-1983 | Chairman of Quality Assurance Committee |
| 1982-1986 | Institutional Review Board, Colima Internal Medical Group |
| 1983-1998 | Chairman of Ethics Committee of Friendly Hills Regional Medical Group |
| 1993-1998 | Clinical Professor of Medicine, University of California School of Medicine, Irvine. |
| 1993-1998 | Chairman of the Department of Internal Medicine, Friendly Hills Medical Group |
| 1999 | Present Clinical Professor, UCLA Medical School |
Appointments
| 1976-1988 | Medical Director, Coronary Care Unit, Whittier Hospital Medical Center |
| 1976-1988 | Medical Director, Medical Education, Whittier Hospital Medical Center |
| 1976-1998 | Medical Director, Whittier Dialysis Center |
| 1984-present | Active Staff, Cedars-Sinai Towers Artificial Kidney Center |
| 1998-present | Associate Physician, Tower Nephrology Medical Group, Beverly Hills Dialysis, Center, Crescent Heights Dialysis Center |
Staff Privileges
| 1976-1988 | Medical Director, Coronary Care Unit, Whittier Hospital Medical Center |
Publications
- Titration of Micro and Ultramico Quantities of Calcium in Blood Serum, Urine and Inorganic Salt Solutions
- Dauer, Alan D., Iwane C., Marik A., and Smith A., Intensive Coronary Care Training Manual, Compiled for Instructional Use, Whittier Hospital Medical Center, 1971
- Journal of Respiratory Diseases, Februaru 1984, Book Review Biology in Health and Diseases, p. 94
- Reviewer for the Journal of Respiratory Diseases, 1982- present
- Illnesses Possibly Associated with Smoking Clove Cigarettes, Center for Diseases Control Morbidity and Mortality Weekly Report (MMWR), May 31, 1985, Vol. 34, No 21
- Terazosin: An Effective Once-Daily Monotherapy for the Treatment of Hypertension, Yorke Medical Group, The American Journal of Medicine.
- EKG of the Month: Digitalis Intoxication vs. Digitalis Need, A94, August 1963, the new Physician
- American College of Physicians in Support of Fellowship Applications:
- Prospective in Renal Transplantation, 1983 Non-Hodgkin.s, Lymphoma, 1983 Lupus Nephritis, 1983 Immune Complex Nephritis Folled by Graves. Disease: A Case History, 1983 IGA Nephropathy, 1983.
- Presentation at the Terazosin Investigators Meeting, Boca Raton, Florida, May 3-5, 1985: Terazosin: An Effective Once-Daily Monotherapy
- Terazosin: An Effective Once-Daily Monotherapy for the Treatment of, The American Journal of Medicine, May 23, 1986, Vol. 80, and p. 29.
- Terazosin: An Effective Once-A-Day Antihypertensive Agent With an Apparent Beneficial Effect on Cholesterol, .Today.s Therapeutic Trends. 4(1); 1-15, 1986.
- Lisinopriol/HCTZ in Essential Hypertension, American Society for Clinical Pharmocology and Therapeutics 1-2, p.64, march 28, 1987
- Enalapril in the Chronic Treatment of Congestive Heart Failure Patients, submitted to the American College of Cardiology.
- Presentation at the Innisbrool Resort & Convention Center, Tampa, Florida, June 5-7, 1987, Terazosin: An F=Effective Once-Daily Monotherapy for the Treatment of Hypertension.
- Serotonergic Appetite Suppression as Treatment of Obesity, Accepted by the International Journal of Obesity, October 11, 1988
Professional Affiliations
- Fellow, America, College of Physicians
- Diplomate of the American Board of Internal Medicine
- American College of Cardiology
- California Society of Internal Medicine
- Los Angeles County Medical Association
- American Society for Clinical Pharmacology and Therapeutics
- American Society of Hypertension, Inc.
- American Society of Nephrology
Community Service
- Past President, Board of Directors, Downey Museum of Art, Downey, California.
- Past President, Board of Directors, Hebrew Academy, Long Beach, California.
- Past member, Rio Hondo Liaison committee, Department of Mental health.
Clinical Study Location
- Tower Nephrology Medical Group, Los Angeles, CA
- DaVita Beverly Hills, Los Angeles, CA
- DaVita Crescent Heights, Los Angeles, CA
Clinical Studies
2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)
| Sub-Investigator | 2014 | Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis |
| Sub-Investigator | 2014 | A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis |
| Sub-Investigator | 2013 | A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis. |
| Sub-Investigator | 2013 | ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia. |
| Sub-Investigator | 2013 | Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease. |
| Sub-Investigator | 2013 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137 |
| Sub-Investigator | 2012 | A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy |
| Sub-Investigator | 2011 | A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis |
| Sub-Investigator | 2011 | Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon) |
| Sub-Investigator | 2011 | A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study |
2010 GCP Certified by the National Cancer Institute
| Sub-Investigator | 2010 | A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease. |
| Sub-Investigator | 2009 | A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor. |
| Sub-Investigator | 2008 | Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia. |
| Sub-Investigator | 2007 | A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin |
| Sub-Investigator | 2007 | Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis |
| Sub-Investigator | 2007 | A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®) |
| Sub-Investigator | 2007 | A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections. |
| Sub-Investigator | 2007 | Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis. |
| Sub-Investigator | 2007 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease. |
| Principal Investigator | 2007 | A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease |
| Sub-Investigator | 2007 | An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency |
| Sub-Investigator | 2006 | Arandomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy. |
| Sub-Investigator | 2006 | Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events. |
| Principal Investigator | 2006 | A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis. |
| Sub-Investigator | 2005 | An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease. |
| Sub-Investigator | 2004 | Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis. |
| Sub-Investigator | 2004 | Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis. |
| Principal Investigator | 2003 | Phase 3 Cinacalcet open label to reach K/DOQI levels |
| Principal Investigator | 2003 | Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce. |
| Sub-Investigator | 2003 | Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study) |
| Principal Investigator | 2003 | Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD). |
| Sub-Investigator | 2002 | Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW). |
| Principal Investigator | 2002 | Phase 3 Placebo-controlled, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease. |
| Sub-Investigator | 2002 | Phase 4 Disease/Case Management of Patients Receiving ARANESP (darbepoetin alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI). |
| Sub-Investigator | 2002 | Phase 4, Multicenter Trial Using Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) and Iron Guided Algorithms to Treat Subjects with Anemia of Chronic Renal Insufficiency (CRI). |
| Sub-Investigator | 2002 | Phase 4 Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) in subjects with Anemia of Chronic Renal Insufficiency (CRI). |
| Principal Investigator | 2002 | Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent on Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis. |
| Principal Investigator | 2001 | Phase 3 A Multicenter, Open-label Extension Study to Assess the Long- term Safety and Efficacy if an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD). |
| Principal Investigator | 2001 | Phase 2 Randomized, double-blind Study to Assess the Efficacy and safety of an Oral Calcimimetic Agent on secondary Hyperparathyroidism of End Stage Renal Disease treated with Hemodialysis. |
| Principal Investigator | 2000 | Phase 2 Pharmacokinetic (PK) Analysis of Chronic Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis (HD). |
| Sub-Investigator | 1999 | Chronic Renal Insufficiency registry in a prospective, observational study designed to gather data on the use of various interventions delivered to patients with renal insufficiency, pre-ESRD. |
| Principal Investigator | 1999 | Randomized Study Comparing the Efficiency of Once Weekly Versus 3 Times Weekly Administration of Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) to Subjects with End-Stage Renal Disease (ESRD) Receiving Hemodialysis. |
| Principal Investigator | 1990-1991 | E.R. Squibb & Sons: Zofenopril Calcium |
| Principal Investigator | 1989-1991 | Burroughs Wellcome Company: Effects of Digoxin Withdrawal on Exercise Tolerance |
| Principal Investigator | 1989-1990 | Miles Pharceuticals: Nifedine |
| Co Investigator | 1988-1990 | Abbott Laboratories: Clarithromycin for Pneumonia |
| Principal Investigator | 1988-1989 | Marion Laboratories: Carizim for Hypertension |
| Principal Investigator | 1988-1989 | Merck Sharp & Dohme: Lovastatin (Mevacor) |
| Principal Investigator | 1987-1990 | Pfizer Pharmaceuticals: Prazosin GITS |
| Principal Investigator | 1987-1988 | Hoechst Roussel Pharmaceuticals Ramipril vs. Enalapril |
| Principal Investigator | 1986-1990 | Ortho Pharmaceutical: Erythropoietin |
| Principal Investigator | 1986-1988 | Eli Lilly and Company: Nizatidine |
| Principal Investigator | 1986-1988 | Smith Kline and French Laboratories: Fenoldopam |
| Principal Investigator | 1986-1987 | Merck Sharp & Dohme Laboratories: Felodipine |
| Principal Investigator | 1986-1989 | Roche laboratories: Cilazorpril vs. Captopril |
| Principal Investigator | 1986-1987 | Merck Sharp & Dohme Laboratories: Aldomet |
| Principal Investigator | 1986-1987 | Wallace Laboratories: Soma |
| Principal Investigator | 1986-1987 | Ciba-Geigy Corporation: Voltaren |
| Principal Investigator | 1986-1988 | Beckitt & Colman Pharmaceuticals: Buprenorphine vs. Morphine |
| Principal Investigator | 1985-1987 | Wyeth Laboratories: Dezocine (Open Label) |
| Principal Investigator | 1985-1987 | Syntex Laboratories: Ketorolac vs. Acetaminophen & Codeine |
| Principal Investigator | 1985-1986 | Eli Lilly & Company Laboratories: Nalfon Sustained Release. |
| Principal Investigator | 1985 | Eli Lilly & Company: Fluoxetine |
| Principal Investigator | 1985-1987 | Merck Sharp & Dohme Laboratories: Enalapril, first Line therapy |
| Principal Investigator | 1985-1986 | Merck Sharp & Dohme Laboratories: Combination Lisinopril And Hydrochlorothiazide |
| Principal Investigator | 1984-1988 | Ayerst Laboratories: Ultradol vs. Ibuprofen, Long Term |
| Principal Investigator | 1984-1985 | Ayerst Laboratories: Ultradol vs. Piroxican and Placebo. |
| Principal Investigator | 1984-1986 | Ayerst laboratories: Betacor vs. Inderal |
| Principal Investigator | 1984-1985 | Merck Sharp & Dohme Laboratories: Meduretic vs. |
| Principal Investigator | 1984-1987 | Merck Sharp & Dohme Laboratories: Enalapril (Open-Label) |
| Principal Investigator | 1983-1986 | Lilly Laboratories: Pinacidil vs. Hydralazine |
| Principal Investigator | 1982-1986 | Abbott Laboratories: Terasozin vs. Placebo and Open Long |
| Principal Investigator | 1981-1983 | Wyeth Laboratories: Indoramin vs. Prazosin and Hydrochlorothiazide |
| Principal Investigator | 1968 | Study of Long-Acting Nitrates on Patients with Coronary and Insufficiency |